Protalix to Present Promising PRX-115 Trial Data
Company Announcements

Protalix to Present Promising PRX-115 Trial Data

Protalix ( (PLX) ) has issued an update.

Protalix BioTherapeutics is set to present promising data from their phase I trial of PRX-115, a novel treatment for uncontrolled gout, at the ACR Convergence 2024. This showcases their innovative plant cell-based protein expression system, ProCellEx, which has already led to FDA-approved products. Investors and market watchers should note Protalix’s strategic partnerships and expanding pipeline targeting key pharmaceutical markets.

For detailed information about PLX stock, go to TipRanks’ Stock Analysis page.

Related Articles
Howard KimPLX Upcoming Earnings Report: What to Expect?
TheFlyProtalix announces repayment of outstanding senior secured convertible notes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App